How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%

Group 1 - Keros Therapeutics, Inc. (KROS) shares have increased by 14.1% over the past four weeks, closing at $17.32, with a mean price target of $23.25 indicating a potential upside of 34.2% [1] - The average price targets from analysts range from a low of $16.00 to a high of $35.00, with a standard deviation of $5.95, suggesting variability in estimates [2] - Analysts show strong agreement on KROS's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for KROS's current year earnings has increased by 484% over the past month, with six estimates revised upward and no negative revisions [12] - KROS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]